The tweet was deleted by the author.
But we saved everything 🙂.
Centene is spotlighting the growing momentum behind Individual Coverage Health Reimbursement Arrangements (ICHRA) as an option for employer-sponsored coverage. Alan Silver, President of ICHRA for Ambetter Health Solutions at Centene, shared views on the potential of this approach.
Silver addressed the flexibility and consumer-driven nature that ICHRA could bring to healthcare coverage. Centene is raising questions about the future direction of employer health benefits.
CNC is currently trading at $63.82, below both the MA-20 ($66.29) and Ichimoku Kijun ($64.63), signaling short-term bearish pressure and marking $64.63 as immediate resistance. The price remains above the MA-50 ($62.99) and well above the MA-200 ($45.71), indicating that the medium- and long-term trends are still structurally bullish. Near-term support sits at $62.99 (MA-50), with key support at $51.72 (MA-100). Immediate resistance is at $64.63 (Ichimoku Kijun), followed by key resistance at $66.29 (MA-20).
MACD on D1 signals strong bullish momentum, while ADX on D1 is supportive but less decisive. RSI on D1 appears neutral to slightly constructive, and CCI is close to neutral. Stoch RSI and BBP on D1 both point to a recent shift toward seller dominance and mild oversold conditions. Momentum readings are mixed, with AO readings neutral. BBP indicates that sellers have the upper hand intraday. CNC has dropped $2.62 (4.01%) from last week's close at $66.44, now trading at the very bottom of its weekly range. Weekly volatility stands at 6.27%. The tone is a steady decline from recent highs. In today’s session, the price has slipped 3.14%, reflecting pronounced downside pressure.
For the upcoming week, the expected trading range is $62.50–$65.50, keeping close to the current price and the established volatility band. The probability of a price increase is very high (more than 80%), given "Buy" signals from RSI-W1, ADX-W1, MACD-W1, and MA-50-W1, making further declines less likely. Baseline scenario: price consolidates sideways between $62.50 and $65.50. Bullish scenario: a break above $65.50 could open the path toward $66.29. Bearish scenario: failure to hold $62.99 support brings $62.00 into view. This forecast range remains well above the 52-week low ($25.08) but below the 52-week high ($69.36), signaling ongoing consolidation after a strong uptrend.
Previously it was reported that Centene faced ongoing investor caution due to membership declines and Medicaid-related revenue pressures, despite its reaffirmed guidance and improved earnings outlook. This article builds on that perspective by highlighting evolving market sentiment, suggesting that sustained progress on cost management and membership stabilization will be critical ahead of the next earnings cycle.